Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
Optimal treatment for advanced cervical cancer after first line chemotherapy remains undefined. Immune checkpoint inhibition with pembrolizumab, a programmed cell death protein 1(PD-1) inhibitor, is under investigation. We analyzed the micro-environmental and molecular genetic profile of tumors from...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2018-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_edaaf9daed3345748f9f4abf25c44aa8 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a N.Y.L. Ngoi |e author |
| 700 | 1 | 0 | |a V. Heong |e author |
| 700 | 1 | 0 | |a X.W. Lee |e author |
| 700 | 1 | 0 | |a Y.Q. Huang |e author |
| 700 | 1 | 0 | |a Y.L. Thian |e author |
| 700 | 1 | 0 | |a B.A. Choo |e author |
| 700 | 1 | 0 | |a D. Lim |e author |
| 700 | 1 | 0 | |a Y.W. Lim |e author |
| 700 | 1 | 0 | |a S.E. Lim |e author |
| 700 | 1 | 0 | |a A. Ilancheran |e author |
| 700 | 1 | 0 | |a R. Soong |e author |
| 700 | 1 | 0 | |a D.S.P. Tan |e author |
| 245 | 0 | 0 | |a Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer |
| 260 | |b Elsevier, |c 2018-05-01T00:00:00Z. | ||
| 500 | |a 2352-5789 | ||
| 500 | |a 10.1016/j.gore.2018.01.009 | ||
| 520 | |a Optimal treatment for advanced cervical cancer after first line chemotherapy remains undefined. Immune checkpoint inhibition with pembrolizumab, a programmed cell death protein 1(PD-1) inhibitor, is under investigation. We analyzed the micro-environmental and molecular genetic profile of tumors from 4 patients with metastatic cervical cancer treated with off-label second-line pembrolizumab in an effort to identify predictive biomarkers. All patients received 2 mg/kg of pembrolizumab, 3-weekly until disease progression. Immunohistochemistry(IHC) for PD-1, PD-L1, CD3 and CD8, as well as next generation sequencing (NGS) for 50 cancer-related genes were performed on tumor samples. All patients tolerated treatment well with no discontinuation of treatment due to toxicity. One patient experienced dramatic and prolonged partial response, and remains stable on pembrolizumab with a progression free survival (PFS) of 21 months at the time of reporting of this series. Three patients experienced disease progression as best response. In the exceptional responder, there was no tumoral expression of PD-L1, however, combined positive score (CPS) for PD-L1 was 1 and we identified somatic mutations in ERBB4(R612W), PIK3CA(E542K) and RB1(E365K). In 2 patients, despite progressive disease defined by RECIST v1.1, symptom stabilization on pembrolizumab was observed. The tumors of both patients had PD-1 expression in ≥1% of stromal lymphocytes. All patients with response or clinical benefit had CPS for PD-L1 ≥ 1. NGS revealed PIK3CA mutations in 3 tumors. Pembrolizumab is a promising therapeutic option in advanced cervical cancer. Further evaluation of biomarkers may guide optimal patient selection. Keywords: Cervical cancer, Pembrolizumab, Immune checkpoint inhibition, Biomakers | ||
| 546 | |a EN | ||
| 690 | |a Gynecology and obstetrics | ||
| 690 | |a RG1-991 | ||
| 690 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | ||
| 690 | |a RC254-282 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Gynecologic Oncology Reports, Vol 24, Iss , Pp 1-5 (2018) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2352578918300092 | |
| 787 | 0 | |n https://doaj.org/toc/2352-5789 | |
| 856 | 4 | 1 | |u https://doaj.org/article/edaaf9daed3345748f9f4abf25c44aa8 |z Connect to this object online. |